Lucid Diagnostics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
360 Madison Ave Fl 25, New York, New Yor...Phone Number
(888) 582-4339Website
www.luciddx.comRevenue
$5.4 MillionStock Symbol
LUCDIndustry
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.Explore more
Lucid Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Lucid Diagnostics
Compare insights from companies similar to Lucid Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$40.1M
51-200
Private
-
2008
MM
Mariam MaghribiShifamed Chief Business Officer & President & CEO, Atia Vision & Tioga Cardiovascular
Lucid Diagnostics Tech Stack
A closer look at the technologies used by Lucid Diagnostics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lucid Diagnostics
Sign Up For FreeTo access detailed company insights
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal... Read More
